Revvity (RVTY)
Market Price (7/28/2026): $108.03 | Market Cap: $12.1 BilInvestor Relations Sector: Health Care | Industry: Health Care Equipment
Revvity (RVTY)
Market Price (7/28/2026): $108.03Market Cap: $12.1 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17% Stock buyback supportStock Buyback 3Y Total is 1.6 Bil Low stock price volatilityVol 12M is 39% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -35%, 3Y Excs Rtn is -78% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 34x, P/EPrice/Earnings or Price/(Net Income) is 50x Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.1% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.0% Key risksRVTY key risks include [1] intense pressure from larger, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17% |
| Stock buyback supportStock Buyback 3Y Total is 1.6 Bil |
| Low stock price volatilityVol 12M is 39% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -35%, 3Y Excs Rtn is -78% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 34x, P/EPrice/Earnings or Price/(Net Income) is 50x |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.1% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.0% |
| Key risksRVTY key risks include [1] intense pressure from larger, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Revvity (RVTY) stock has gained about 25% since 3/31/2026 because of the following key factors:
1. Strong Fiscal Q1 2026 Financial Performance Exceeded Expectations.
Revvity reported its fiscal Q1 2026 earnings on May 5, 2026, with an adjusted EPS of $1.06, surpassing the consensus estimate of $1.02 by $0.04. Quarterly revenue reached $711.12 million, exceeding analyst expectations of $704.07 million and representing a 7.0% year-over-year increase. Following this positive earnings report, Revvity's shares increased by 6.7%.
2. Upgraded Analyst Outlook and Increased Price Targets.
S&P Global Ratings revised its outlook on Revvity from negative to stable on July 13, 2026, affirming the company's BBB issuer credit rating. The agency anticipates Revvity's adjusted leverage to decrease to 2.7x by the end of fiscal year 2026 and 2.4x in fiscal year 2027. Several analysts responded by raising their price targets, including TD Cowen to $120 from $115 on May 6, 2026, Barclays to $105 from $95 on May 7, 2026, Evercore ISI Group to $125 from $110 on July 6, 2026, and TD Cowen again to $130 from $120 on July 15, 2026.
Show more
Revvity (RVTY) stock has gained about 25% since 3/31/2026 because of the following key factors:
1. Strong Fiscal Q1 2026 Financial Performance Exceeded Expectations.
Revvity reported its fiscal Q1 2026 earnings on May 5, 2026, with an adjusted EPS of $1.06, surpassing the consensus estimate of $1.02 by $0.04. Quarterly revenue reached $711.12 million, exceeding analyst expectations of $704.07 million and representing a 7.0% year-over-year increase. Following this positive earnings report, Revvity's shares increased by 6.7%.
2. Upgraded Analyst Outlook and Increased Price Targets.
S&P Global Ratings revised its outlook on Revvity from negative to stable on July 13, 2026, affirming the company's BBB issuer credit rating. The agency anticipates Revvity's adjusted leverage to decrease to 2.7x by the end of fiscal year 2026 and 2.4x in fiscal year 2027. Several analysts responded by raising their price targets, including TD Cowen to $120 from $115 on May 6, 2026, Barclays to $105 from $95 on May 7, 2026, Evercore ISI Group to $125 from $110 on July 6, 2026, and TD Cowen again to $130 from $120 on July 15, 2026.
3. Strategic Expansion into AI-driven Software Solutions.
Revvity demonstrated a strategic pivot towards higher-margin, software-led life sciences workflows through new product launches. On June 22, 2026, the company launched "Signals AI," a native agentic framework designed to accelerate scientific research and development by enabling natural language interaction with complex data. This was further expanded on July 1, 2026, with the integration of Anthropic Claude into the Signals AI Ecosystem. Additionally, Revvity introduced its Signals for Startups program, offering enterprise-grade informatics tools to emerging biotech companies.
4. Positive Financial Projections and Robust Free Cash Flow.
The company's financial stability and future prospects contributed to investor confidence. S&P Global Ratings forecasts an improvement in Revvity's profit margin to the 30% to 31% range in fiscal years 2026 and 2027, driven by cost-optimization and internal AI initiatives. The firm also projects annual free operating cash flow to exceed $500 million in the coming years, with $400 million to $500 million allocated to share buybacks. For fiscal year 2026, Revvity's full-year EPS guidance is set between $5.20 and $5.30.
Show less
Stock Movement Drivers
Fundamental Drivers
The 23.5% change in RVTY stock from 3/31/2026 to 7/27/2026 was primarily driven by a 22.9% change in the company's P/E Multiple.| (LTM values as of) | 3312026 | 7272026 | Change |
|---|---|---|---|
| Stock Price ($) | 87.49 | 108.07 | 23.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,856 | 2,902 | 1.6% |
| Net Income Margin (%) | 8.4% | 8.3% | -2.2% |
| P/E Multiple | 41.0 | 50.4 | 22.9% |
| Shares Outstanding (Mil) | 113 | 112 | 1.1% |
| Cumulative Contribution | 23.5% |
Market Drivers
3/31/2026 to 7/27/2026| Return | Correlation | |
|---|---|---|
| RVTY | 23.5% | |
| Market (SPY) | 13.6% | 36.8% |
| Sector (XLV) | 11.5% | 36.5% |
Fundamental Drivers
The 11.9% change in RVTY stock from 12/31/2025 to 7/27/2026 was primarily driven by a 7.5% change in the company's P/E Multiple.| (LTM values as of) | 12312025 | 7272026 | Change |
|---|---|---|---|
| Stock Price ($) | 96.56 | 108.07 | 11.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,813 | 2,902 | 3.2% |
| Net Income Margin (%) | 8.4% | 8.3% | -2.2% |
| P/E Multiple | 46.9 | 50.4 | 7.5% |
| Shares Outstanding (Mil) | 115 | 112 | 3.2% |
| Cumulative Contribution | 11.9% |
Market Drivers
12/31/2025 to 7/27/2026| Return | Correlation | |
|---|---|---|
| RVTY | 11.9% | |
| Market (SPY) | 8.7% | 46.0% |
| Sector (XLV) | 6.0% | 38.6% |
Fundamental Drivers
The 12.1% change in RVTY stock from 6/30/2025 to 7/27/2026 was primarily driven by a 24.8% change in the company's P/E Multiple.| (LTM values as of) | 6302025 | 7272026 | Change |
|---|---|---|---|
| Stock Price ($) | 96.38 | 108.07 | 12.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,770 | 2,902 | 4.8% |
| Net Income Margin (%) | 10.3% | 8.3% | -20.2% |
| P/E Multiple | 40.4 | 50.4 | 24.8% |
| Shares Outstanding (Mil) | 120 | 112 | 7.4% |
| Cumulative Contribution | 12.1% |
Market Drivers
6/30/2025 to 7/27/2026| Return | Correlation | |
|---|---|---|
| RVTY | 12.1% | |
| Market (SPY) | 20.6% | 43.1% |
| Sector (XLV) | 22.8% | 48.1% |
Fundamental Drivers
The -8.2% change in RVTY stock from 6/30/2023 to 7/27/2026 was primarily driven by a -74.0% change in the company's Net Income Margin (%).| (LTM values as of) | 6302023 | 7272026 | Change |
|---|---|---|---|
| Stock Price ($) | 117.77 | 108.07 | -8.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3,024 | 2,902 | -4.0% |
| Net Income Margin (%) | 31.8% | 8.3% | -74.0% |
| P/E Multiple | 15.5 | 50.4 | 226.1% |
| Shares Outstanding (Mil) | 126 | 112 | 12.9% |
| Cumulative Contribution | -8.2% |
Market Drivers
6/30/2023 to 7/27/2026| Return | Correlation | |
|---|---|---|
| RVTY | -8.2% | |
| Market (SPY) | 72.6% | 45.9% |
| Sector (XLV) | 28.9% | 51.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| RVTY Return | 40% | -30% | -22% | 2% | -13% | 14% | -22% |
| Peers Return | 32% | -27% | -13% | -1% | 1% | 7% | -10% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| RVTY Win Rate | 83% | 50% | 42% | 33% | 42% | 43% | |
| Peers Win Rate | 73% | 37% | 48% | 47% | 50% | 51% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 43% | |
Max Drawdowns [4] | |||||||
| RVTY Max Drawdown | -25% | -42% | -43% | -15% | -35% | -30% | |
| Peers Max Drawdown | -19% | -39% | -39% | -23% | -39% | -28% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TMO, DHR, A, BIO, ILMN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/27/2026 (YTD)
How Low Can It Go
| Event | RVTY | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -22.3% | -18.8% |
| % Gain to Breakeven | 28.7% | 23.1% |
| Time to Breakeven | 227 days | 79 days |
| 2020 COVID-19 Crash | ||
| % Loss | -29.3% | -33.7% |
| % Gain to Breakeven | 41.4% | 50.9% |
| Time to Breakeven | 71 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -25.4% | -19.2% |
| % Gain to Breakeven | 34.0% | 23.8% |
| Time to Breakeven | 67 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -10.9% | -3.7% |
| % Gain to Breakeven | 12.3% | 3.9% |
| Time to Breakeven | 117 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -17.4% | -12.2% |
| % Gain to Breakeven | 21.1% | 13.9% |
| Time to Breakeven | 53 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -11.2% | -6.8% |
| % Gain to Breakeven | 12.6% | 7.3% |
| Time to Breakeven | 39 days | 15 days |
In The Past
Revvity's stock fell -22.3% during the 2025 US Tariff Shock. Such a loss loss requires a 28.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | RVTY | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -22.3% | -18.8% |
| % Gain to Breakeven | 28.7% | 23.1% |
| Time to Breakeven | 227 days | 79 days |
| 2020 COVID-19 Crash | ||
| % Loss | -29.3% | -33.7% |
| % Gain to Breakeven | 41.4% | 50.9% |
| Time to Breakeven | 71 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -25.4% | -19.2% |
| % Gain to Breakeven | 34.0% | 23.8% |
| Time to Breakeven | 67 days | 105 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -33.1% | -17.9% |
| % Gain to Breakeven | 49.5% | 21.8% |
| Time to Breakeven | 132 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -20.1% | -15.4% |
| % Gain to Breakeven | 25.2% | 18.2% |
| Time to Breakeven | 96 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -57.0% | -53.4% |
| % Gain to Breakeven | 132.8% | 114.4% |
| Time to Breakeven | 420 days | 1085 days |
In The Past
Revvity's stock fell -22.3% during the 2025 US Tariff Shock. Such a loss loss requires a 28.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Revvity (RVTY)
Revvity, Inc. (RVTY) is a global provider of essential products, services, and solutions for the diagnostics, life sciences, and applied services markets. The company equips scientists, researchers, and healthcare professionals worldwide with advanced tools and technologies to accelerate scientific discovery, improve human health through diagnostics, and ensure environmental and product safety.
Through its Discovery & Analytical Solutions segment, Revvity offers a comprehensive portfolio including instruments, reagents, software, and contract research services. These solutions are crucial for enhancing research breakthroughs in life sciences, characterizing environmental health (air, water, soil), supporting agriculture and food production, and providing analytical instrumentation for industrial sectors such as chemicals, semiconductors, and energy.
Revvity's Diagnostics segment focuses on developing and providing instruments, reagents, and assay platforms for the early detection of genetic disorders and infectious diseases. This segment's products are vital for screening conditions like Down syndrome, hypothyroidism, and various metabolic conditions, as well as enabling advanced genomic workflows for applications in oncology, immunodiagnostics, and drug discovery, serving laboratories, hospitals, and pharmaceutical companies globally.
AI Analysis | Feedback
Here are 1-2 brief analogies to describe Revvity (RVTY):
- It's like the Thermo Fisher Scientific for scientific research and diagnostic tools.
- Think of it as the Danaher of high-tech instruments and services for labs, healthcare, and environmental analysis.
AI Analysis | Feedback
- Life Sciences Research Technologies: Revvity provides instruments, reagents, informatics, software, detection, and imaging technologies to enhance research breakthroughs in life sciences.
- Contract Research and Laboratory Services: The company offers specialized contract research and laboratory services primarily for the life sciences research market.
- Environmental and Food Analysis Solutions: Revvity supplies analytical technologies, solutions, and services for assessing the health of air, water, and soil, as well as solutions for farmers and food producers.
- Industrial Analytical Instrumentation: The company offers analytical instrumentation and solutions for various industrial markets, including chemical, semiconductor, energy, and petrochemical industries.
- Diagnostic Products and Platforms: Revvity provides instruments, reagents, assay platforms, and software for the early detection of genetic disorders and infectious diseases.
- Genomic Workflow Technologies: The company develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery.
AI Analysis | Feedback
Revvity (RVTY) primarily sells its products, services, and solutions to other companies and organizations, rather than directly to individuals. Its major customers fall into the following categories:
- Pharmaceutical and biotechnology companies
- Laboratories (including contract research and analytical laboratories)
- Academic and research institutions
- Public health authorities
- Private healthcare organizations
- Doctors and healthcare providers
- Government agencies (including those in environmental, industrial, and public health sectors)
AI Analysis | Feedback
AI Analysis | Feedback
Prahlad Singh, PhD - President and Chief Executive Officer
Prahlad Singh was appointed President and Chief Executive Officer of Revvity (formerly PerkinElmer, Inc.) in 2019. He led the company through a significant transformation, including overseeing the divestiture of its Applied, Food and Enterprise Services businesses to New Mountain Capital, which led to the creation of Revvity. Prior to joining PerkinElmer in 2014, Dr. Singh served as General Manager of GE Healthcare's Women's Health business. He also held senior executive roles in strategy, business development, and mergers and acquisitions at both GE Healthcare and Philips Healthcare. Dr. Singh holds a PhD in chemistry and an MBA.
Max Krakowiak - Senior Vice President and Chief Financial Officer
Max Krakowiak is the Senior Vice President and Chief Financial Officer at Revvity, a role he was appointed to in August 2022. He has been an integral part of Revvity's finance leadership team since 2018. Before becoming CFO, Mr. Krakowiak served as VP of Corporate Finance, overseeing financial planning and analysis, as well as the commercial and business development finance organizations. He also acted as the company's chief of staff for finance, focusing on global finance transformation. Prior to Revvity, Mr. Krakowiak spent seven years at GE, most recently as a member of the executive leadership team in their corporate audit staff, where he worked on corporate strategy, external investigations, and investor relations across GE's global operating segments. He is a graduate of the GE Financial Management leadership program and holds a bachelor's degree in finance from Fordham University. Notably, he was also a minor league baseball player for the Seattle Mariners organization.
Joel Goldberg - Senior Vice President, Administration, General Counsel and Secretary
Joel Goldberg serves as Senior Vice President, Administration, General Counsel and Secretary for Revvity. In this role, he provides expert insights and strategic thinking on a variety of legal, regulatory, and policy issues affecting the company. He leads dedicated and solutions-driven teams that collaborate across the business to offer support and guidance on various corporate matters.
Miriame Victor - Senior Vice President and Chief Commercial Officer
Miriame Victor is the Senior Vice President and Chief Commercial Officer at Revvity. She is responsible for leading a global team dedicated to bringing innovative products and solutions to market that address customer needs and expand human potential in health and science. Ms. Victor is a proponent of accessible, easy-to-use diagnostics and breakthrough solutions for advancing human health.
Tajinder Vohra - Senior Vice President, Global Operations
Tajinder Vohra is the Senior Vice President of Global Operations at Revvity. He oversees the company's manufacturing, supply chain, customer care, and distribution functions. With nearly 30 years of experience in operations management, Mr. Vohra leads a global team that works closely with R&D and Product Management to launch and manufacture products across Revvity's Life Sciences and Diagnostics businesses.
AI Analysis | Feedback
The key risks to Revvity's business include:
-
Intense Competition: Revvity operates in highly competitive life sciences and diagnostics sectors, facing numerous large and specialized players such as Thermo Fisher Scientific, Agilent Technologies, Danaher, Siemens Healthineers, Roche, and Abbott Laboratories. This dynamic environment necessitates continuous innovation to maintain market share against well-capitalized rivals, and ongoing consolidation among competitors could further threaten Revvity's market position.
-
Regulatory and Geopolitical Headwinds, Particularly in China: Revvity is significantly exposed to evolving regulatory landscapes and geopolitical factors. Specifically, changes in China's regulatory policies, such as DRG (Diagnosis-Related Group) reimbursement reforms that favor cheaper single-marker diagnostic tests over multiplex panels, have led to double-digit declines in Revvity's immunodiagnostics business in the region. This makes China a "major drag" on its diagnostics segment, with persistent uncertainty around future healthcare policy changes. Broader macroeconomic pressures, including tariffs, trade barriers, and foreign exchange fluctuations, also impact profit margins and disrupt supply chains globally.
-
Technological Disruption and the Imperative for Continuous Innovation: The rapid pace of technological advancement in the life sciences and diagnostics industries poses a significant risk. Revvity must continuously introduce new products and solutions to avoid technological obsolescence and prevent the loss of market share to competitors. Failure to keep pace with these changes and invest in timely innovation could adversely affect its competitive standing.
AI Analysis | Feedback
AI Analysis | Feedback
Discovery & Analytical Solutions Segment
- Life Sciences Market (products, services, research): The global life science market size is projected to grow from USD 100.88 billion in 2025 to approximately USD 278.40 billion by 2034. The global life science research services market, a component of this, is calculated at USD 35.37 billion in 2025 and is predicted to increase to approximately USD 96.26 billion by 2035.
- Contract Research Organization (CRO) Services: The global contract research organization (CRO) services market size was valued at USD 92.27 billion in 2025 and is projected to reach USD 199.28 billion by 2034.
- Analytical Instrumentation Market: The global analytical instrumentation market size was valued at USD 41.8 billion in 2025 and is expected to grow to USD 71.9 billion in 2035. Another estimate places the global analytical instrumentation market size at USD 58.67 billion in 2025, projected to reach around USD 102.7 billion by 2035.
- Process Analytical Technology Market: The global process analytical technology market size is calculated at USD 4.00 billion in 2025 and is projected to surpass approximately USD 11.01 billion by 2035.
Diagnostics Segment
- Diagnostic Testing Market: The global diagnostic testing market size was calculated at USD 207.96 billion in 2025 and is predicted to surpass around USD 281.56 billion by 2035.
- Genetic Testing Market: The global genetic testing market size was valued at USD 37.32 billion in 2025 and is projected to grow to USD 93.94 billion by 2034. A more specific segment, the global genetic disease testing market, was valued at USD 937 million in 2024 and is projected to grow to USD 1.97 billion by 2032.
- Genomics Market (including genomic workflows for diagnostics): The global genomics market is estimated to be valued at USD 50.1 billion in 2025 and is projected to reach USD 304.8 billion by 2035.
- Clinical Laboratory Services Market: The global clinical laboratory services market size was valued at USD 291.01 billion in 2025 and is projected to grow to USD 545.79 billion by 2034.
AI Analysis | Feedback
Here are the expected drivers of future revenue growth for Revvity (RVTY) over the next 2-3 years:
- New Product Launches and Software Innovations: Revvity anticipates a significant new product introduction cycle, particularly within its Signals business. Launches such as Synthetica, BioDesign, and Labgistics are expected to boost growth, with the Signals business projected to double in five years. Additionally, the Phenologic.AI™ software, introduced in January 2025, is designed to enhance cellular imaging workflows. In the Diagnostics segment, the company launched the IDS i20 ChLIA diagnostic analyzer and received U.S. regulatory approval for the T-SPOT TB test automation in Q2 2025.
- Growth in Diagnostics Segment (Immunodiagnostics and Reproductive Health): The Diagnostics segment is a key growth area, with the company seeing strong performance in both immunodiagnostics and reproductive health. Reproductive health and newborn screening are exhibiting "outsized growth," driven by geographic expansion and the detection of new disorders. Revvity aims to significantly increase its market penetration in U.S. immunodiagnostics, with a goal to double its revenue share from 20% to 40%.
- Stabilization and Improvement in Pharma Biotech Market: Revvity expects continued stabilization and growth in the broader pharma biotech market, along with anticipated improvements in pharmaceutical spending. The Life Science Solutions segment has shown differentiated performance, with expectations for improved platform sales, and sales into the pharma biotech sector saw low single-digit growth in Q4 2025 and for the full year.
- Strategic Re-segmentation and Operational Efficiency: The company is undertaking a strategic re-segmentation, effective fiscal year 2025, by integrating most of its Applied Genomics business into a new Life Sciences Solutions business. This restructuring is intended to streamline operations, create synergies, and sharpen customer focus, which is expected to position Revvity for sustained success across its key markets. Furthermore, Revvity is implementing its operating model to enhance operational efficiency and execution.
- Favorable Pricing Impact: Revvity anticipates a consistent positive impact from pricing, expecting at least 100 basis points of favorable price annually in the coming years.
AI Analysis | Feedback
Share Repurchases
- Revvity, Inc. authorized a new $1 billion share repurchase program in November 2024, replacing a previous program announced in May 2023.
- Over two and a half years leading up to March 2026, the company repurchased 15 million shares, representing 12% of its outstanding shares.
- Between March 31, 2025, and June 29, 2025, Revvity repurchased 3,102,232 shares for $292.66 million, contributing to a total of $586.86 million under the November 2024 buyback program.
Share Issuance
- The number of outstanding shares increased by 12.62% in 2021.
- Shares outstanding decreased by 2.28% in 2023, 2.25% in 2024, and 6.03% in 2025.
Outbound Investments
- In 2025, Revvity announced its acquisition of ACD/Labs, a provider of scientific software solutions, to enhance its Signals Software capabilities in analytical characterization and molecular design.
- In March 2025, Revvity acquired Project Farma, which offers consulting, quality, regulatory, and marketing services to the biopharma sector.
- In 2021, Revvity (then PerkinElmer) acquired BioLegend, Inc. for $5.7 billion to strengthen its Life Sciences segments, and also acquired Nexcelom and Oxford Immunotec in the same year.
Capital Expenditures
- Capital expenditures were -$73.52 million in the trailing 12 months (as of a recent report, likely late 2025/early 2026).
- For the full year 2025, capital expenditures totaled -$53.351 million, with -$18.501 million in Q4 2025.
- Capital expenditures for the full year 2024 were -$62.194 million.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 192.99 |
| Mkt Cap | 33.9 |
| Rev LTM | 5,812 |
| Op Inc LTM | 1,208 |
| FCF LTM | 1,030 |
| FCF 3Y Avg | 1,005 |
| CFO LTM | 1,290 |
| CFO 3Y Avg | 1,268 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 4.7% |
| Rev Chg 3Y Avg | 0.4% |
| Rev Chg Q | 5.9% |
| QoQ Delta Rev Chg LTM | 1.4% |
| Op Inc Chg LTM | 2.5% |
| Op Inc Chg 3Y Avg | -2.3% |
| Op Mgn LTM | 18.9% |
| Op Mgn 3Y Avg | 14.9% |
| QoQ Delta Op Mgn LTM | 0.6% |
| CFO/Rev LTM | 19.9% |
| CFO/Rev 3Y Avg | 19.9% |
| FCF/Rev LTM | 16.0% |
| FCF/Rev 3Y Avg | 16.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 33.9 |
| P/S | 5.0 |
| P/Op Inc | 30.4 |
| P/EBIT | 26.2 |
| P/E | 34.3 |
| P/CFO | 23.2 |
| Total Yield | 3.3% |
| Dividend Yield | 0.3% |
| FCF Yield 3Y Avg | 3.7% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Life Sciences | 1,431 | 1,399 | 1,293 | 898 |
| Diagnostics | 1,425 | 1,356 | 2,020 | 2,933 |
| Revenue purchase accounting adjustments | -1 | -3 | ||
| Total | 2,856 | 2,755 | 3,312 | 3,828 |
| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Life Sciences | 458 | 467 | 503 | 282 |
| Diagnostics | 344 | 354 | 782 | 1,433 |
| Significant environmental matters | 1 | 0 | 0 | |
| Asset impairment | 0 | -23 | 0 | |
| Purchase accounting adjustments | -1 | 0 | -46 | -41 |
| Acquisition and divestiture-related costs | -4 | -25 | -40 | -63 |
| Transformation costs | -9 | 0 | ||
| Significant litigation matters and settlements | -12 | -8 | 1 | |
| Corporate expenses | -29 | -42 | -73 | -77 |
| Restructuring and other, net | -56 | -17 | -14 | -18 |
| Amortization of intangible assets | -336 | -359 | -371 | -257 |
| Total | 357 | 347 | 743 | 1,258 |
| $ Mil | 2023 | 2022 | 2021 | 2019 |
|---|---|---|---|---|
| Corporate expenses | 114 | 130 | 131 | 87 |
| Current and long-term assets of discontinued operations | 1,694 | 1,700 | ||
| Diagnostics | 3,992 | 4,693 | 4,229 | 3,369 |
| Life Sciences | 8,330 | 8,478 | 3,601 | 3,083 |
| Total | 14,130 | 15,001 | 7,960 | 6,539 |
Price Behavior
| Market Price | $108.07 | |
| Market Cap ($ Bil) | 12.1 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -8.1% | |
| 50 Days | 200 Days | |
| DMA Price | $104.58 | $98.35 |
| DMA Trend | up | up |
| Distance from DMA | 3.3% | 9.9% |
| 3M | 1YR | |
| Volatility | 42.9% | 38.3% |
| Downside Capture | 57.80 | 149.18 |
| Upside Capture | 153.28 | 126.83 |
| Correlation (SPY) | 36.1% | 43.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.69 | 1.07 | 1.22 | 1.43 | 1.38 | 1.07 |
| Up Beta | -0.98 | 0.22 | 1.07 | 1.21 | 1.42 | 1.00 |
| Down Beta | 3.04 | 2.40 | 1.54 | 1.70 | 1.19 | 1.05 |
| Up Capture | 75% | 167% | 143% | 162% | 161% | 95% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 12 | 24 | 36 | 69 | 130 | 370 |
| Down Capture | 1% | 6% | 101% | 131% | 134% | 106% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 9 | 17 | 27 | 56 | 122 | 381 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RVTY | |
|---|---|---|---|---|
| RVTY | 6.3% | 39.1% | 0.24 | - |
| Sector ETF (XLV) | 22.0% | 15.7% | 1.07 | 47.0% |
| Equity (SPY) | 17.6% | 12.7% | 1.00 | 43.8% |
| Gold (GLD) | 20.8% | 28.1% | 0.66 | 14.1% |
| Commodities (DBC) | 29.6% | 19.5% | 1.21 | -15.1% |
| Real Estate (VNQ) | 13.9% | 14.1% | 0.69 | 38.8% |
| Bitcoin (BTCUSD) | -46.0% | 43.0% | -1.31 | 27.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RVTY | |
|---|---|---|---|---|
| RVTY | -6.4% | 34.4% | -0.13 | - |
| Sector ETF (XLV) | 6.8% | 15.0% | 0.27 | 55.9% |
| Equity (SPY) | 13.2% | 17.1% | 0.59 | 52.8% |
| Gold (GLD) | 17.2% | 18.4% | 0.75 | 12.5% |
| Commodities (DBC) | 9.7% | 19.5% | 0.38 | 4.7% |
| Real Estate (VNQ) | 3.3% | 18.9% | 0.07 | 49.6% |
| Bitcoin (BTCUSD) | 15.8% | 53.5% | 0.47 | 21.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RVTY | |
|---|---|---|---|---|
| RVTY | 7.4% | 30.9% | 0.30 | - |
| Sector ETF (XLV) | 10.1% | 16.6% | 0.49 | 58.4% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 56.6% |
| Gold (GLD) | 11.4% | 16.1% | 0.58 | 10.8% |
| Commodities (DBC) | 6.9% | 18.0% | 0.30 | 12.2% |
| Real Estate (VNQ) | 5.2% | 20.7% | 0.21 | 43.6% |
| Bitcoin (BTCUSD) | 58.0% | 66.2% | 0.98 | 14.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/8/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/5/2026 | 6.7% | 14.4% | 16.8% |
| 2/2/2026 | -1.6% | -6.6% | -11.8% |
| 10/27/2025 | -1.7% | -5.4% | 1.7% |
| 7/28/2025 | -8.3% | -14.9% | -11.1% |
| 4/28/2025 | 0.8% | -0.3% | -2.2% |
| 1/31/2025 | -0.6% | -6.1% | -13.0% |
| 11/4/2024 | 3.1% | 1.2% | -5.0% |
| 7/29/2024 | 9.1% | 7.1% | 5.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 13 | 10 | 11 |
| # Negative | 11 | 14 | 13 |
| Median Positive | 4.7% | 7.8% | 5.7% |
| Median Negative | -1.6% | -5.2% | -10.8% |
| Max Positive | 9.1% | 14.4% | 16.8% |
| Max Negative | -16.1% | -14.9% | -17.8% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/5/2026 | 6.7% | 14.4% | 16.8% |
| 2/2/2026 | -1.6% | -6.6% | -11.8% |
| 10/27/2025 | -1.7% | -5.4% | 1.7% |
| 7/28/2025 | -8.3% | -14.9% | -11.1% |
| 4/28/2025 | 0.8% | -0.3% | -2.2% |
| 1/31/2025 | -0.6% | -6.1% | -13.0% |
| 11/4/2024 | 3.1% | 1.2% | -5.0% |
| 7/29/2024 | 9.1% | 7.1% | 5.2% |
| 4/29/2024 | 3.5% | -0.9% | 10.2% |
| 2/1/2024 | 1.9% | -4.0% | -0.1% |
| 10/30/2023 | -16.1% | -9.9% | -10.3% |
| 8/1/2023 | -0.3% | -0.1% | -3.2% |
| 5/11/2023 | -5.0% | -7.4% | -10.8% |
| 2/14/2023 | -0.5% | -7.5% | -11.7% |
| 11/8/2022 | -1.6% | 10.7% | 7.8% |
| 8/1/2022 | 5.0% | 0.4% | -11.0% |
| 5/3/2022 | 2.8% | -5.1% | -1.3% |
| 2/1/2022 | 6.2% | 6.0% | 2.7% |
| 11/2/2021 | -1.3% | -1.0% | 2.1% |
| 7/26/2021 | 4.7% | 10.9% | 10.4% |
| 5/4/2021 | 6.9% | 9.1% | 8.5% |
| 2/2/2021 | -7.5% | -3.6% | -17.8% |
| 10/28/2020 | 3.5% | 8.6% | 3.9% |
| 7/28/2020 | 5.9% | 6.9% | 5.7% |
| SUMMARY STATS | |||
| # Positive | 13 | 10 | 11 |
| # Negative | 11 | 14 | 13 |
| Median Positive | 4.7% | 7.8% | 5.7% |
| Median Negative | -1.6% | -5.2% | -10.8% |
| Max Positive | 9.1% | 14.4% | 16.8% |
| Max Negative | -16.1% | -14.9% | -17.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/12/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 02/25/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/12/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 02/25/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
| 12/31/2021 | 03/03/2022 | 10-K |
| 09/30/2021 | 11/09/2021 | 10-Q |
| 06/30/2021 | 08/10/2021 | 10-Q |
| 03/31/2021 | 05/11/2021 | 10-Q |
| 12/31/2020 | 03/02/2021 | 10-K |
| 09/30/2020 | 11/10/2020 | 10-Q |
| 06/30/2020 | 08/11/2020 | 10-Q |
| 03/31/2020 | 05/12/2020 | 10-Q |
| 12/31/2019 | 02/25/2020 | 10-K |
| 09/30/2019 | 11/05/2019 | 10-Q |
| 06/30/2019 | 08/06/2019 | 10-Q |
Recent Forward Guidance
Updated 7/8/2026Latest: Q1 2026 Earnings Reported 5/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 2.81 Bil | 2.83 Bil | 2.84 Bil | -5.0% | Lowered | Guidance: 2.98 Bil for 2026 | |
| 2026 Organic Revenue Growth | 3.0% | 3.5% | 4.0% | 1.0% | Raised | Guidance: 2.5% for 2026 | |
| 2026 Adjusted EPS | 5.2 | 5.25 | 5.3 | -2.8% | Lowered | Guidance: 5.4 for 2026 | |
Prior: Q4 2025 Earnings Reported 2/2/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 2.96 Bil | 2.98 Bil | 2.99 Bil | 4.2% | Higher New | Guidance: 2.85 Bil for 2025 | |
| 2026 Organic Revenue Growth | 2.0% | 2.5% | 3.0% | -16.7% | -0.5% | Lower New | Guidance: 3.0% for 2025 |
| 2026 Adjusted EPS | 5.35 | 5.4 | 5.45 | 9.1% | 45.0% | Higher New | Guidance: 4.95 for 2025 |
Q3 2025 Earnings Reported 10/27/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Revenue | 2.83 Bil | 2.85 Bil | 2.88 Bil | -0.2% | Lowered | Guidance: 2.86 Bil for 2025 | |
| 2025 Organic Revenue Growth | 2.0% | 3.0% | 4.0% | 0 | Affirmed | Guidance: 3.0% for 2025 | |
| 2025 Adjusted EPS | 4.9 | 4.95 | 5 | 1.0% | 5.0% | Raised | Guidance: 4.9 for 2025 |
Insider Activity
Updated 7/22/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gonzales, Anita | Vice President and CAO | Direct | Sell | 7222026 | 109.48 | 85 | 9,306 | 788,365 | Form |
| 2 | Gonzales, Anita | Vice President and CAO | Direct | Sell | 4222026 | 92.80 | 80 | 7,424 | 679,203 | Form |
| 3 | Victor, Miriame | Please See Remarks | Direct | Sell | 2262026 | 97.13 | 1,862 | 180,856 | 1,760,190 | Form |
| 4 | McMurry-Heath, Michelle | Direct | Sell | 2252026 | 97.26 | 600 | 58,356 | 411,702 | Form | |
| 5 | Singh, Prahlad R | Please See Remarks | Direct | Sell | 2062026 | 100.21 | 25,525 | 2,557,859 | 12,046,538 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gonzales, Anita | Vice President and CAO | Direct | Sell | 7222026 | 109.48 | 85 | 9,306 | 788,365 | Form |
| 2 | Gonzales, Anita | Vice President and CAO | Direct | Sell | 4222026 | 92.80 | 80 | 7,424 | 679,203 | Form |
| 3 | Victor, Miriame | Please See Remarks | Direct | Sell | 2262026 | 97.13 | 1,862 | 180,856 | 1,760,190 | Form |
| 4 | McMurry-Heath, Michelle | Direct | Sell | 2252026 | 97.26 | 600 | 58,356 | 411,702 | Form | |
| 5 | Singh, Prahlad R | Please See Remarks | Direct | Sell | 2062026 | 100.21 | 25,525 | 2,557,859 | 12,046,538 | Form |
| 6 | Goldberg, Joel S | Please See Remarks | Direct | Sell | 2062026 | 100.21 | 12,717 | 1,274,357 | 4,333,734 | Form |
| 7 | Vohra, Tajinder S | Please See Remarks | Direct | Sell | 2042026 | 104.50 | 5,756 | 601,502 | 1,091,189 | Form |
| 8 | Michas, Alexis P | The Cayre and Alexis Michas Foundation Corp. | Sell | 8282025 | 89.01 | 500 | 44,505 | 647,103 | Form |
Investor Activity (13F)
Updated Jul 28, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| RGM Capital, LLC | $147.0 Mil | 7.1% | 17 | Exited | 13F |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.